The 23rd edition of CPHI China 2025 took place at the Shanghai New International Expo Centre, where Leadsynbio unveiled its complete portfolio across three core sectors—Human Nutrition, Animal Nutrition, and Pharmaceutical Intermediates—alongside the latest innovations in synthetic biology. At booth W4F49, the company attracted strong interest from global partners, fostering in-depth discussions on cooperation and future opportunities.

On-site, Leadsynbio highlighted its key offerings: Florfenicol as a high-quality antibacterial raw material, NMN/NAD series for healthy aging and metabolic support, and 25-Hydroxy Vitamin D3 for animal nutrition. Leveraging transformative biomanufacturing processes, these products deliver enhanced production efficiency, lower costs, and significant reductions in carbon emissions, providing customers with more competitive and sustainable solutions. Today, Leadsynbio is recognized as one of the leading global suppliers in these specialized markets, with products distributed to nearly 20 countries and regions worldwide.

To support its growth, Leadsynbio has built a global R&D and production network, anchored by its headquarters in Suzhou and an international innovation center, with large-scale manufacturing bases in Hunan and Anhui. Several pipeline products are now in critical development stages, set to create strong synergies with the existing portfolio. Meanwhile, the company is accelerating its progress in international certifications, strengthening its position for global market expansion.

Looking ahead, Leadsynbio remains committed to original innovation and global deployment, integrating its innovation chain with the industrial value chain. The company will continue to provide the worldwide market with cost-effective, eco-friendly, and sustainable biomanufacturing products and solutions, empowering customers to achieve both economic performance and environmental responsibility.